Mubasher: Global Response Aid (GRA) and the Indian Dr. Reddy’s Laboratories signed an agreement with Japan’s FujiFilm Corporation for the production and distribution of Avigan, a potential treatment of coronavirus (COVID-19).
The tripartite agreement allows GRA and Dr. Reddy’s Laboratories to develop, manufacture, and sell the anti-viral drug in all countries other than Japan, China and Russia, according to a statement on Sunday.
Avigan is being tested in several countries as a therapeutic to decrease the severity of coronavirus symptoms and shorten the recovery time for patients.
“The partnership will eventually cover manufacturing and distribution for markets that are home to 6 billion of the world’s 7.8 billion people.”
GRA will use the global logistics network of its parent company Agility which owns more than 30 facilities worldwide, complying with good distribution practices (GDP) and offering a wide range of logistics services.
The CEO of Agility, Tarek Sultan, said, “We need to be producing a high volume of treatment courses and have a distribution network and plan in place so make Avigan available to as many frontline health providers as possible. GRA’s partnership with Dr. Reddy’s and FujiFilm gives us that capability.”